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Membrane protein biogenesis poses enormous challenges to cellular
protein homeostasis and requires effective molecular chaperones.
Compared with chaperones that promote soluble protein folding,
membrane protein chaperones require tight spatiotemporal coordi-
nation of their substrate binding and release cycles. Here we define
the chaperone cycle for cpSRP43, which protects the largest family
of membrane proteins, the light harvesting chlorophyll a/b-binding
proteins (LHCPs), during their delivery. Biochemical and NMR analyses
demonstrate that cpSRP43 samples three distinct conformations. The
stromal factor cpSRP54 drives cpSRP43 to the active state, allowing
it to tightly bind substrate in the aqueous compartment. Bidentate
interactions with the Alb3 translocase drive cpSRP43 to a partially
inactive state, triggering selective release of LHCP’s transmem-
brane domains in a productive unloading complex at the mem-
brane. Our work demonstrates how the intrinsic conformational
dynamics of a chaperone enables spatially coordinated substrate
capture and release, which may be general to other ATP-indepen-
dent chaperone systems.
membrane protein biogenesis | molecular chaperone |
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Protein homeostasis is essential for all cells and requires propercontrol of the folding, localization, and interactions of pro-
teins. The biogenesis of membrane proteins poses a particular
challenge to protein homeostasis. Before arrival at the membrane,
newly synthesized membrane proteins need to traverse aqueous
cellular compartments where they are highly prone to aggregation.
Thus, the posttranslational targeting of membrane proteins relies
critically on effective molecular chaperones that maintain nascent
membrane proteins in translocation competent states. Many ex-
amples illustrate the intimate link between chaperone function
and membrane protein biogenesis: SecB, Skp, and SurA protect
bacterial outer membrane proteins (1–5), and Hsp70 homologs
assist the import of mitochondrial or chloroplast proteins (6).
Our understanding of membrane protein chaperones lags far
behind that for soluble proteins, such as DnaK and GroEL. All
chaperones need to switch between “open” and “closed” con-
formations to allow substrate release and binding, respectively.
For many chaperones that promote the folding of soluble pro-
teins, these switches can be driven either by ATPase cycles, such
as Hsp70 (7) and GroEL (8), or by changes in environmental
conditions, such as the acid-induced HdeA (9, 10) and oxidation-
induced Hsp33 (11). In contrast, membrane protein chaperones
must regulate their action spatially: they must effectively capture
substrate proteins in the aqueous phase, and then facilely and
productively release them at the target membrane. With few
exceptions (1, 2), how membrane protein chaperones achieve
spatiotemporal coordination of their chaperone cycle is not well
understood.
The light harvesting chlorophyll a/b-binding proteins (LHCPs)
provide an excellent model system to address these questions.
Like >95% of organellar proteins, LHCPs are initially synthe-
sized in the cytosol and imported across the chloroplast envelope
in a largely unfolded state with the assistance of the LHCP
translocation defect protein (12). In the stroma, LHCPs are
protected in a soluble “transit complex” by the chloroplast signal
recognition particle (cpSRP), comprised of cpSRP43 and cpSRP54
(13). Via interactions between the GTPase domains of cpSRP54
and its receptor cpFtsY, LHCPs are delivered to the Alb3 trans-
locase and inserted into the thylakoid membrane (13–17). LHCPs
comprise more than 50% of the proteins in the thylakoid mem-
brane and are the most abundant membrane protein family on
earth. Their sheer abundance, high aggregation propensity, and
crucial roles in energy generation of green plants demand highly
effective chaperone(s) during their biogenesis, making this a
robust system to understand the function and mechanism of mem-
brane protein chaperones.
Previous work showed that the cpSRP43 subunit in cpSRP
binds tightly to and quantitatively prevents the aggregation of
multiple members of the LHCP family, demonstrating that
cpSRP43 is responsible for chaperone function (18, 19). cpSRP43
is comprised of multiple protein-interaction domains: three
chromodomains (CDs) and an ankyrin repeat domain (A1–A4)
between CD1 and CD2 (Fig. 1A) (14). Biochemical and crystal-
lographic analyses showed that a conserved Tyr204 in the third
ankyrin repeat recognizes a FDPLGL motif in L18, a conserved
18-amino acid sequence between TM2 and TM3 of LHCP (20–
22). In addition, aromatic cages in CD2 provide binding sites for
a conserved RRKR motif in the C terminus of cpSRP54 (23). A
recent study found that cpSRP54 can induce compaction of
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cpSRP43 and enhance L18 peptide binding threefold, suggesting
that cpSRP54 could positively regulate cpSRP43 (24). Finally,
cpSRP43 also interacts directly with the C-terminal stromal do-
main of the Alb3 translocase (termed Alb3CT) that mediates the
membrane insertion of LHCP (25–29), suggesting a potential
mechanism to couple substrate release to the correct localization
of LHCP and its imminent membrane insertion (30). The ability of
cpSRP43 to directly bind Alb3 may also explain findings in earlier
genetic studies that, when both cpSRP54 and cpFtsY are deleted,
cpSRP43 by itself can mediate the targeting and insertion of some
LHCP family members, albeit less efficiently (30).
Nevertheless, the molecular mechanism of cpSRP43’s chap-
erone function remains elusive. Where is the substrate binding
domain of this chaperone located? How does it interact with the
targeting (cpSRP54) and translocation (Alb3) machineries to
achieve accurate spatiotemporal regulation of its activity? More
fundamentally, in the absence of an ATPase module, what pro-
pels the substrate binding and release cycle for this chaperone?
In this work, a combination of biochemical and solution NMR
studies addresses these questions and for the first time, to our
knowledge, defines the complete chaperone cycle for a chaper-
one dedicated to integral membrane proteins. Our results show
that cpSRP43 inherently exchanges between three distinct con-
formations; this allows it to be readily turned “on” by cpSRP54 in
the aqueous stroma to enable tight substrate binding and to be
readily switched to less active conformations by Alb3 at the
membrane to enable facile substrate unloading. Furthermore, we
show that Alb3 specifically induces the release of substrate TMDs,
but not the L18 motif, from cpSRP43, suggesting a highly pro-
ductive, stepwise mechanism for handover of the membrane
protein substrates to the translocation machinery.
Results
Defining the Substrate-Binding Domain for cpSRP43. In previous
work, a fragment comprising CD1 and the ankyrin repeat do-
main of cpSRP43 (CD1Ank) could not chaperone LHCP (19).
Nevertheless, crystallographic analysis (20) revealed an additional
20-amino acid-long helix, not present in other ankyrin repeat
proteins, that bridges the ankyrin repeat domain and CD2 (here
termed the bridging helix or BH; Fig. 1A). Intriguingly, addition of
this BH to CD1Ank was necessary and sufficient to restore
chaperone activity. Using a light scattering assay (19), which
directly monitors the formation of large protein aggregates, we
found that a protein fragment containing CD1, the ankyrin re-
peat domain, and BH (CD1Ank-BH) prevented the aggregation
of LHCP fivefold more efficiently than full-length cpSRP43 (Fig.
1B). In a more stringent disaggregation assay (19), which mon-
itors the ability of cpSRP43 to reverse preformed large LHCP
aggregates, CD1Ank-BH was also more efficient than full-length
cpSRP43 (Fig. 1C). Consistent with previous results (19), re-
moval of BH (i.e., CD1Ank) abolished chaperone activity in both
assays (Fig. 1 B and C).
A key substrate recognition motif of cpSRP43 is the L18 se-
quence between TM2 and TM3 of LHCP (21, 31). To test
whether the BH is important for this recognition, we measured
cpSRP43 binding with L18 based on the increase in fluorescence
anisotropy of a HiLyte-Fluor488–labeled L11 peptide, which
comprises the minimal binding motif in L18 (20, 22). The
CD1Ank-BH fragment binds tightly to the dye-labeled L11
peptide, with a Kd value (15 nM) twofold lower than that of WT
cpSRP43 (25 nM) (Fig. 1D). Consistent with the results of the
light scattering assay, removal of the BH abolished this binding
(Fig. 1D). To rule out potential artifacts introduced by dye la-
beling, we also measured the binding of the WT L18 sequence to
cpSRP43 by using it as a competitor of dye-labeled L11 in the
anisotropy assay. These experiments showed that L18 effectively
bound to both WT cpSRP43 and CD1Ank-BH and competed
with dye-labeled L11 (Fig. 1E).
Together with previous mutational analyses (19), these results
establish that the CD1Ank-BH fragment comprises the minimal
substrate binding domain (SBD) of cpSRP43 and that the
bridging helix connecting the ankyrin repeat domain to CD2 is
crucial for substrate binding.
Chromodomain 2 Regulates Chaperone Activity. Intriguingly, we
isolated many mutations in the neighboring CD2 that affect
chaperone activity of the SBD. One class of these mutants re-
sides in the linker connecting BH to CD2 (Fig. 2A, cyan). The
chaperone activity of cpSRP43 is strongly correlated with the
flexibility of the linker sequence, with longer and more flexible
linkers [GSCFNGT (the Intein construct) or GSGSG insertion],
leading to higher activities of cpSRP43 in preventing (Fig. 2B)
and reversing (Fig. 2C) LHCP aggregation, whereas a con-
formationally more restricted linker 2P (two Pro replacing the
natural QV) leads to lower activity (Fig. 2 B and C).
A second class of mutants resides in the conserved hydro-
phobic core of CD2 (Fig. 2A, yellow, and Fig. S1). Virtually every
single mutation introduced into this core hyperactivates the
Fig. 1. The CD1Ank-BH fragment is necessary and sufficient for the chap-
erone activity of cpSRP43. (A) Schematic of cpSRP43. CD, chromodomain; A1–
A4, ankyrin repeats 1–4; BH, bridging helix; SBD, substrate binding domain.
(B) Binding of LHCP to wildtype cpSRP43 (black) and to the CD1Ank (green)
and CD1Ank-BH (red) fragments of cpSRP43 were measured by the ability of
cpSRP43 to prevent LHCP aggregation (Materials and Methods). The data
were fit to Eq. 1 and gave apparent Kd values of 170 and 32 nM for LHCP
binding to cpSRP43 and to the CD1Ank-BH fragment, respectively. (C) CD1Ank-
BH (red) can reverse LHCP aggregation more efficiently than WT cpSRP43
(black), but the CD1Ank (green) fragment cannot. (D) Binding of HiLyte-
Fluor 488–labeled L11 peptide to WT and mutant cpSRP43, detected by
fluorescence anisotropy. The data were fit to Eq. 2 and gave Kd values of 25
and 15 nM for the binding of dye-labeled L11 peptide to cpSRP43 (black) and
to the CD1Ank-BH (red) fragment, respectively. (E) Binding of the L18
peptide to WT and mutant cpSRP43 was measured using L18 as a competitor
of dye-labeled L11. The data were fit to Eq. 3 and gave Kappi values of 1.1 and
0.5 μM for cpSRP43 (black) and the CD1Ank-BH (red) fragment, respectively.
Errors of Kd and K
app
i values were estimated to be ±10% (SD) based on at
least two measurements (technical replicates).
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chaperone (Fig. 2D). Quantitative analysis of some of the mu-
tants further showed that cpSRP43’s substrate binding is en-
hanced 10- to 20-fold in each mutant (Fig. 2 E and F). Thus,
although CD2 does not directly bind the substrate protein, it
regulates the conformation and activity of the SBD.
The cpSRP54 M Domain Drives cpSRP43 to the Active Conformation.
In the stroma, cpSRP43 is bound to cpSRP54, the other subunit
of cpSRP. The C terminus of the cpSRP54 M-domain (termed
54M) binds at CD2 in the vicinity of the BH (Fig. 2A) (23, 32),
placing it in an optimal position for regulating interdomain in-
teractions of cpSRP43. In support of this notion, 54M enhances
the binding affinity of LHCP to WT cpSRP43 sixfold under
stringent low salt conditions (100 mM NaCl; Fig. 3A). This re-
sult is consistent with a recent study, which also reported that
cpSRP43 becomes more compact and binds the L18 peptide
threefold more strongly in the presence of cpSRP54 (24). Im-
portantly, the superactive mutant, intein-cpSRP43, is not further
stimulated by 54M (Fig. 3B). In contrast, a soft mutation C175A
reduced cpSRP43’s chaperone activity ∼18-fold; this partially
crippled mutant is much more strongly activated by 54M (Fig.
3C). Together, these results strongly suggest that 54M and
superactive mutations in CD2 drive the same activating confor-
mational change in cpSRP43 and that interdomain dynamics
control cpSRP43’s chaperone activity (Fig. 3D).
CpSRP43 has been bound to shift between monomer and
higher oligomeric forms depending on solution ionic strength
(19). To test whether the activating conformational change of
cpSRP43 is related to changes in its oligmeric state, we carried
out gel filtration chromatography and analytical ultracentrifuga-
tion analyses (Fig. S2). The results showed that, under high salt
Fig. 3. The cpSPR54 M-domain activates cpSRP43 for substrate binding. The
abilities of chaperone to prevent LHCP aggregation were measured for WT
cpSRP43 (A), superactive intein-cpSRP43 (B), and partially defective mutant
cpSRP43(C175A) (C) in the absence (●) and presence (○) of 54M. The data
were fit to a Michaelis–Menton equation and gave apparent Kd values of
0.26 and 1.5 μM for WT cpSRP43 with and without 54M (A), 0.20 and 0.41 μM
for intein-cpSRP43 with and without 54M (B), and 0.08 and 3.0 μM for
cpSRP43(C175A) with and without 54M (C). In A and B, activities were
measured under 100 mM NaCl, a stringent condition under which cpSRP43
exhibits slightly reduced activity, to overcome the saturation effects with
highly active chaperone constructs and better reveal the stimulatory effects
of 54M. (D) Scheme depicting the conformational change of cpSRP43 on
substrate binding. TMD, transmembrane domain.
Fig. 2. Mutations in CD2 hyperactivate the chaperone. (A) Crystal structure
of cpSRP43 CD1Ank-BH-CD2 fragment bound to 54M peptide [Protein Data
Bank (PDB) ID code 3UI2]. Cyan shows the linker (V266, F267) between BH
and CD2, yellow shows residues mutated in the hydrophobic core of CD2,
magenta highlights the BH, and red shows the 54M peptide. (B and C)
Chaperone activity of cpSRP43 linker mutants, measured by prevention (B)
and reversal (C) of LHCP aggregation. The data in B were fitted to Eq. 1 and
gave apparent Kd values of 33, 100, 177, and 256 nM for LHCP binding
to intein-cpSRP43 (red), GSGSG-cpSRP43 (orange), WT cpSRP43 (black), and
2P-cpSRP43 (cyan), respectively. (D) Many point mutations in the conserved
hydrophobic core of CD2 activate chaperone activity. Chaperone activities
were measured by prevention of LHCP aggregation using 1 μM LHCP and
4 μMWT or mutant cpSRP43. Error bars represent SD, with n = 2. To rule out
potential involvements of CD3, all measurements were made with the ΔCD3
construct. A soft mutation, C175A, was present in all constructs to increase
the sensitivity of the mutational screen under these conditions. (E and F)
Mutants Y287R (E) and W299R (F) enhance LHCP binding to cpSRP43 >10-
fold. Chaperone activities were measured and analyzed as in B and gave
apparent Kd values of 1.9 μM, 168 nM, and 141 nM for cpSRP43(C175A),
cpSRP43(Y287R_C175A), and cpSRP43(W299_C175A), respectively. Errors of
Kd values were estimated to be ±10% (SD) based on at least two measure-
ments (technical replicates).
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conditions (≥200 mM NaCl), WT or superactive intein-cpSRP43
is predominantly a monomer (Fig. S2 A and D). cpSRP43 also
binds the L11 peptide and 54M in monomeric form (Fig. S2 B,
E, and F). Under low salt conditions (50 mM NaCl), cpSRP43
predominantly runs on Superdex 200 as a dimer (Fig. S2C) as
previously observed (19). Importantly, binding of L11 shifts di-
meric cpSRP43 toward the monomeric form (Fig. S2C). These
results, together with the previous observation that the shift of
cpSRP43 to dimeric complexes at lower ion strength is correlated
with loss of chaperone activity (19), strongly suggest that mono-
meric cpSRP43 is chaperone active. Thus, the substrate- and 54M-
induced rearrangement of cpSRP43 reflects an intramolecular
conformational change, rather than changes in its oligomeric state.
NMR Spectroscopy Directly Reveals Chaperone Conformational Dynamics.
To directly probe for conformational dynamics in cpSRP43, we used
transverse relaxation optimized (TROSY) NMR spectroscopy. We
assigned the cpSRP43 backbone resonances using 3D triple reso-
nance TROSY spectra of 2H,13C,15N-labeled cpSRP43 and the
CD1Ank-BH fragment; assignments for several CD2 cross-peaks
in full-length cpSRP43 were obtained by transferring published as-
signments of the isolated CD2CD3 fragment (33) (SI Materials
and Methods). We were able to assign the amide 15N, 1HN, 13Cα,
and 13Cβ resonances for 80% of residues (Fig. S3).
Intriguingly, the number of NMR cross-peaks in the 1H-15N
TROSY spectrum of cpSRP43 far exceeded the number of res-
idues in the protein. This puzzle was resolved during NMR as-
signments: we found that at least 12 residues in CD1 (highlighted
in Fig. 4G in blue) give rise to two 1H-15N cross-peaks in the
TROSY spectrum that have identical 13Cα and 13Cβ chemical
shifts (examples for S92 and A95 are shown in Fig. S4 A and B).
This observation indicates that the component cross-peaks in the
TROSY spectra arise from the same amino acids and represent
two distinct conformations of cpSRP43 in slow exchange on the
chemical shift timescale.
Importantly, the relative intensities of the component cross-
peaks change in different constructs and in response to different
ligands. An example for S92 is shown in Fig. 4, additional examples
are shown in Fig. S5, and a summary for all 12 residues is shown
in Fig. S6. In full-length cpSRP43, the intensities of the two
component cross-peaks are comparable (Fig. 4B and Fig. S5). In
the inactive CD1Ank construct, the upfield peak is dominant
(Fig. 4A). In contrast, in the CD1Ank-BH construct or the
superactive mutant intein-cpSRP43, which binds LHCP two- to
fivefold more tightly than full-length cpSRP43 (Figs. 1B and 2B),
the downfield peak becomes more intense (Fig. 4 C and D).
When cpSRP43 is bound to the L18 peptide or to the activator,
54M, or the C-terminal peptide of 54M that binds cpSRP43
(54M peptide), the downfield peak is dominant (Fig. 4 E and F
and Fig. S5 A and B). Additional titration experiments with L18
and 54M peptide (Fig. S5 A and B) corroborated that the down-
field peak can be assigned to the active conformation of cpSRP43
conducive to substrate binding. Further, the relative intensity of
this peak is strongly correlated with chaperone activity (Fig. 4H
and Fig. S6).
Collectively, the biochemical and NMR data demonstrate that
the SBD of cpSRP43 exchanges between active and inactive
conformations that are regulated by CD2, by the substrate, and
by interaction with the cpSRP54 M-domain.
Bidentate Interactions of Alb3 with cpSRP43 Drive Substrate Release.
Recent data showed that cpSRP43 directly interacts with the
C-terminal stromal domain of Alb3 (Alb3CT). However, which
site(s) in cpSRP43 interact with Alb3CT is extensively debated
(25–27, 29). To resolve this question, we titrated Alb3CT into
cpSRP43 and monitored changes in the TROSY spectra. We
found that Alb3CT substantially (>90%) broadened a specific
set of cross-peaks in CD3 (Fig. S7 A and C), in contrast to the
absence of any substrate- or 54M-induced perturbations in this
domain. Many perturbed cross-peaks map to an extensive sur-
face displaying conserved acidic residues and two aromatic res-
idues (Fig. 5A), suggesting this to be a binding site for Alb3CT.
This observation is consistent with a recent study in which a peptide
corresponding to motif IV in Alb3CT is found to bind at an acidic
surface in CD3 (29).
Fig. 4. Conformational dynamics of cpSRP43 correlates with its chaperone activity. (A–F) Component cross-peaks for Ser92 in the TROSY spectrum of 2H,15N-
labeled CD1Ank fragment (A), full-length cpSRP43 (B), CD1Ank-BH fragment (C), intein-cpSRP43 (D), cpSRP43 bound to 54M peptide (E), and cpSRP43 bound
to the L18 peptide (F). (G) Crystal structure of CD1Ank-BH fragment (PDB ID code 3DEP) highlighting the residues in CD1 (blue) for which component cross
peaks reflecting the conformational dynamics of cpSRP43 have been unambiguously assigned. Green shows Tyr204 in Ank3, which binds L18 (cyan). Magenta
highlights the bridging helix. (H) Correlation between the chaperone activity (% soluble LHCP observed with 0.625 μM chaperone) of each construct or
complex and the relative intensity of the downfield component cross-peak.
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To biochemically test this model, we generated two charge
reversal mutants in CD3, E352R/D355R/D358R (3R; Fig. 5A,
green), and E338R/Y339A/D348R/W351A (2RA; Fig. 5A, cyan).
We measured the binding of Alb3CT to WT and mutant
cpSRP43 based on the anisotropy change of fluorescein labeled
at Alb3CT(S371C). Consistent with previous measurements (25,
26), WT cpSRP43 bound Alb3CT with an equilibrium dissocia-
tion constant (Kd) of 18 μM in this assay. Binding was weakened
ninefold on deletion of CD3 (Fig. 5B, red), consistent with an
important role of CD3 in cpSRP43-Alb3 binding (25). Both
charge reversal mutants in CD3, cpSRP43(3R) and cpSRP43
(2RA), weakened the binding of Alb3CT fourfold (Fig. 5B).
Alb3CT contains two conserved motifs, II and IV, that could
interact with cpSRP43 (Fig. 5C) (25). Both motifs, especially
motif IV, are enriched in basic residues, providing strong can-
didates for interacting with the acidic patch in CD3. We there-
fore introduced charge reversal mutations into motif II (M2_3E)
or motif IV (M4_5E) of Alb3CT (Fig. 5C). Both mutations sig-
nificantly weakened the binding of Alb3CT to cpSRP43 (Fig. 5 D
and E, blue). Importantly, when the charge reversal mutants
cpSRP43(3R) and Alb3CT(M4_5E) were combined to restore elec-
trostatic complementarity, binding was partially rescued (Fig. 5D,
green). In contrast, rescue was not observed when cpSRP43(3R) was
combined with mutant Alb3CT(M2_3E) (Fig. 5E, green). These
results suggest a specific electrostatic interaction between motif IV
in Alb3CT and the acidic surface in CD3 of cpSRP43.
To provide additional evidence for this model and to probe
the function of Alb3CT, we developed an independent assay in
which a preformed, soluble cpSRP43•LHCP complex is chal-
lenged with Alb3CT. If interaction with Alb3CT releases sub-
strate from cpSRP43, this would lead to aggregation of LHCP
that can be monitored in real time using light scattering (Fig.
5F). Indeed, addition of Alb3CT led to the reappearance of large
LHCP aggregates in a dose-dependent manner (Fig. S8A). This
result indicates that the hydrophobic TMDs of LHCP are no
longer protected by cpSRP43 on Alb3CT binding and provides a
robust assay to analyze the interaction and activity of Alb3CT.
Both charge reversal mutants of Alb3CT, M2_3E and M4_5E,
display severely compromised activities in this release assay
(Fig. 5 G and H), supporting the importance of both motifs in
Alb3CT activity. Importantly, combining the charge reversal
mutant cpSRP43(3R) with Alb3CT(M4_5E) restored release
activity (Fig. 5J), whereas the combination with Alb3CT(M2_3E)
did not (Fig. 5I). Thus, in agreement with the recent structural
analysis (29), cpSRP43 CD3 provides a platform to specifically
bind motif IV in Alb3CT. Our results further show that this in-
teraction is electrostatic in nature and important for the ability
of Alb3CT to induce substrate release from cpSRP43.
In addition to CD3, Alb3CT also induced substantial broadening
of 17 cross-peaks in the TROSY spectrum of cpSRP43 that map
to the SBD (Fig. S7 A and C). This observation was corroborated
when the TROSY experiment was repeated with the CD1Ank-
BH construct: even in the absence of CD2 and CD3, addition of
Alb3CT-induced broadening or shifts of a specific set of cross-peaks
in the TROSY spectrum of CD1Ank-BH (Fig. 6A and Fig. S7B).
Seven of the Alb3CT-perturbed cross-peaks map to CD1; another
three map to Ank3 (Fig. 6B). Thus, Alb3CT also contacts the SBD.
The simplest model to explain these results is that Alb3CT
makes bidentate interactions with cpSRP43 in both the SBD and
CD3. To test this model, we deleted motif II or IV of Alb3CT
(Fig. 6C, ΔM2 and ΔM4, respectively). We measured the binding
of WT and mutant Alb3CT to cpSRP43 by using them as com-
petitors of fluorescein-labeled Alb3CT in the anisotropy assay
(Fig. 6D). ΔM2 and ΔM4 weakened the binding of Alb3CT to
cpSRP43 two- and sixfold, respectively (Fig. 6D). Both mutations
also abolished the ability of Alb3CT to trigger LHCP release
from cpSRP43 (Fig. 6E). The same effects were observed
with charge reversal mutations in Alb3CT motifs II and IV
Fig. 5. Chromodomain 3 of cpSRP43 binds motif IV of Alb3CT. (A) A struc-
tural model of CD3 (PDB ID code 1X32) highlighting the mutated resi-
dues. (B) Binding of fluorescein-labeled Alb3CT(S371C) to WT and mutant
cpSRP43 were measured by changes in fluorescence anisotropy. The data
were fit to Eq. 2 and gave Kd values of 18, >60, >63, and >160 μM for
WT cpSRP43 and mutants 2RA, 3R, and ΔCD3, respectively. The anisotropy
value of mutants was normalized to the same end point as WT cpSRP43.
(C ) Schematics of WT and charge reversal mutants of Alb3CT. (D and E )
Binding of mutant Alb3CT(M4_5E) (D) and Alb3CT(M2_3E) (E ) to WT
cpSRP43 and mutant cpSRP43(3R), measured and analyzed as in B. The
dashed lines indicate binding between WT Alb3CT and cpSRP43 from B
and are shown for comparison. (F ) Scheme for the LHCP TMD release assay.
M2 and M4 denote Alb3CT motifs II and IV, respectively. (G–J) Alb3CT-
induced TMD release from cpSRP43 for the reaction of WT cpSRP43 with
mutant Alb3CT(M2_3E) (G), WT cpSRP43 with Alb3CT(M4_5E) (H), mutant
cpSRP43(3R) with mutant Alb3CT(M2_3E) (I), and mutant cpSRP43(3R) with
mutant Alb3CT(M4_5E) (J). The arrows indicate time of Alb3CT addition.
Red, blue, and green indicate addition of 5, 10, and 20 μM Alb3CT, re-
spectively. The dashed lines denote data of WT cpSRP43 with 5 μM Alb3CT
and are shown for comparison.
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(Fig. 5 D, E, G, and H). Together, these data provide strong
evidence that Alb3CT uses motifs II and IV to make bidentate
interactions with cpSRP43. The much larger effects of each
mutant in the LHCP release assay than on cpSRP43-Alb3 binding
(Fig. 6 D vs. E) further suggests that, although each motif could
bind cpSRP43 at sufficiently high concentrations, the ability of
Alb3CT to trigger substrate release requires the interactions me-
diated by both motifs.
If a bidentate interaction with Alb3CT was required to release
LHCP from cpSRP43, then the spacing between motifs II and IV
would also be important for this activity. In WT Alb3, these two
motifs are bridged by a ∼72-amino acid unstructured linker se-
quence, rendering it plausible that the two motifs can span the
distance between the SBD and CD3 of cpSRP43. To test the
importance of this spacing, we shortened the linker sequence
(Fig. 6C, mutants ΔL20, ΔL40, and ΔL47). Although mutant
ΔL20 did not exhibit a significant defect, further deletion of the
linker sequence in mutants ΔL40 and ΔL47 compromised the
ability of Alb3CT to induce LHCP release from cpSRP43 (Fig.
6F). Collectively, these data provide strong evidence for a bidentate
interaction between Alb3CT and cpSRP43 that are essential to
release LHCP from cpSRP43 at the membrane translocase.
Alb3CT Drives cpSRP43 to a Less Active Conformation. How does
Alb3CT trigger substrate release from cpSRP43? Given that
cpSRP43 samples between active and inactive conformations
(Figs. 2–4), an attractive hypothesis is that Alb3CT drives cpSRP43
to a less active form. To test this model, we used two independent
approaches. First, we took advantage of cpSRP43 variants,
CD1Ank-BH and CD1Ank, which reside predominantly in the
active and inactive conformations, respectively, and tested their
binding with Alb3CT using the fluorescence anisotropy assay.
We found that Alb3CT exhibits significant interactions with the
CD1Ank fragment, although the interaction is 18-fold weaker
than with full-length cpSRP43, consistent with the model that the
SBD provides another binding site for Alb3CT (Fig. 7A). Im-
portantly, Alb3CT bound to the CD1Ank fragment two- to
threefold more strongly than to the CD1Ank-BH fragment,
suggesting that it preferentially interacts with a cpSRP43 in a less
active conformation. The stronger interaction of CD1Ank with
Alb3CT than CD1Ank-BH also ruled out the possibility that
irreversible misfolding of CD1Ank is responsible for its lack of
chaperone activity.
In the second approach, we took advantage of the TROSY
spectra of cpSRP43, in which the relative intensity of component
cross-peaks from individual amide groups directly detects cpSRP43
subpopulations in active and inactive conformations. Of the 12
residues in cpSRP43 for which component cross-peaks can be
Fig. 6. Bidentate interaction of Alb3CT with cpSRP43. (A) Alb3CT-induced
perturbation of cross-peaks in the TROSY spectra of 2H,15N-labeled CD1Ank-
BH fragment. Spectra in the absence and presence of Alb3CT are shown in
black and red, respectively. (B) Structure of CD1Ank-BH (PDB ID code 3DEO)
highlighting residues for which NMR cross-peaks are perturbed by Alb3CT.
Red denotes residues for which cross-peaks are broadened >70%; blue de-
notes residues whose cross-peaks are shifted by Alb3CT. Green shows Tyr204
in Ank3 where L18 binds. (C) Schematic of the mutant Alb3CT constructs
used in this study. ΔM2 and ΔM4 denote deletion of motifs II and IV, re-
spectively, ΔL denotes deletion of linker sequence. (D) Binding of WT Alb3CT
(black) and mutant ΔM2 (red) and ΔM4 (blue) to cpSRP43, measured by their
ability to compete with fluorescein-labeled Alb3CT(S371C) for binding to
cpSRP43 and detected by fluorescence anisotropy. The data were fit to Eq. 3
and gave Kappi values of 41, 99, and 237 μM for WT Alb3CT and mutants ΔM2
and ΔM4, respectively. (E and F) LHCP release assays were carried out as
outlined in Fig. 5F for WT Alb3CT (black), mutants ΔM2 (red) and ΔM4 (blue)
(E), and mutants ΔL20 (blue), ΔL40 (orange) and ΔL47 (green) (F).
Fig. 7. Alb3CT preferentially binds and induces a less active conformation
of cpSRP43. (A) Binding of Alb3CT to full-length cpSRP43 (black) and to the
CD1Ank (green) and CD1Ank-BH (red) fragments, measured as in Fig. 5B. The
data were fit to Eq. 2 and gave Kd values of 12, 216, and >530 μM for WT
cpSRP43, CD1Ank, and CD1ANk-BH, respectively. Errors for Kd were esti-
mated to be ±10% (SD) based on at least two technical replicates. (B) Region
of the TROSY spectrum showing the component cross-peaks for Ser92 in 2H,
15N-labeled cpSRP43 in complex with Alb3CT. (C) The relative intensities of
the cross-peaks corresponding to the inactive chaperone conformation are
reduced by 54M (red bars) and enhanced by subsequent addition of Alb3CT
(green bars). Data are shown for indicated residues in 2H, 15N-labeled intein-
cpSRP43. Relative intensities were determined from cross-peak heights.
(D) 54M and Alb3CT bind to intein-cpSRP43 simultaneously. The cross-peaks
for Tyr287 in the TROSY spectra of 2H, 15N-labeled intein-cpSRP43 are shown.
The peak was shifted on 54M binding (red), and this perturbation persists on
subsequent addition of Alb3CT (green). (E) Scheme depicting the cobinding
of 54M and Alb3CT to cpSRP43. M2, Alb3CT motif II; M4, Alb3CT motif IV.
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unambiguously assigned, residues S92, R93, Y102, L103 exhibited
an Alb3CT-induced increase in the relative intensity of the peak
that arise from the inactive conformation (Fig. 7B and Figs. S5C
and S6). These results provide independent support for the model
that Alb3CT biases cpSRP43 to a less active conformation.
In the targeting pathway, Alb3CT must interact with and release
substrates from the LHCP•cpSRP43•cpSRP54 complex. To test
whether this is possible, we sequentially added the 54M peptide,
followed by Alb3CT, during 2D-TROSY experiments with the
superactive intein-cpSRP43 (to mimic the conformation of sub-
strate-bound cpSRP43). For five residues (S92, R93, T94, Y102,
and L103), the intensity of the component cross-peaks repre-
senting the inactive conformation was significantly reduced on the
addition of 54M, but these inactive peaks regained significant in-
tensity on subsequent addition of Alb3CT (Fig. 7C). The effect of
Alb3CT did not arise from dissociation of 54M from cpSRP43, as
the binding of 54M to cpSRP43 could be detected by shifts of
specific cross-peaks corresponding to residues in and near CD2
(Fig. 7D and Fig. S9), and the 54M-induced perturbation of these
cross-peaks remained even after the addition of Alb3CT (Fig. 7D).
Collectively, the biochemical and NMR data strongly suggest
that Alb3CT induces cpSRP43 to a less active conformation (Fig.
7E). The fact that this transition was observed with only a subset
of residues further suggests that Alb3CT does not drive cpSRP43
into the completely inactive form but rather induces structural
transitions in part of the cpSRP43 molecule. This notion is fur-
ther supported by results in the following section.
Alb3CT Specifically Releases Substrate TMDs from cpSRP43. Our
previous work showed that cpSRP43 binds LHCP via two sets of
interactions: recognition of the L18 motif in loop 2 and pro-
miscuous hydrophobic interactions with the TMDs in LHCP
(22). When the cpSRP43•LHCP complex was challenged by
Alb3CT in the release assay, the light scattering data indicated
that Alb3CT antagonizes the interaction of substrate TMDs with
cpSRP43 such that they are no longer protected from aggrega-
tion (Fig. 5F and Fig. S8A). To test whether Alb3CT also an-
tagonizes the interaction of cpSRP43 with the L18 motif, we
measured the binding of HiLyte-Fluor488–labeled L11 peptide
to cpSRP43 based on fluorescence anisotropy (Fig. 8A). In-
triguingly, the binding of L11 to cpSRP43 was unaffected, if not
slightly stronger, in the presence of Alb3CT (Fig. 8A). To rule
out artifacts from dye labeling, we also measured the binding of
unlabeled L18 peptide to cpSRP43 by using it as a competitor of
dye-labeled L11 (Fig. 8B). This experiment yielded the same
result: L18 binds to cpSRP43 with comparable affinity with or
without Alb3CT present. These data indicate that Alb3CT spe-
cifically antagonizes the interaction of cpSRP43 with the sub-
strate TMDs, but does not affect the interaction of this chaperone
with the L18 motif.
To test this model in the context of full-length LHCP, we
reperformed the LHCP release assay except that, instead of
monitoring the release reaction by light scattering, we monitored
FRET between a donor dye (Atto488) labeled in the L18 motif
of LHCP (G158C) and an acceptor dye [tetramethylrhodamine
(TMR)] labeled at the native Cys297 of cpSRP43 (Fig. S8B). In
contrast to the release of TMDs detected by light scattering, the
FRET assay showed no changes in, if not slightly higher, FRET
efficiency between LHCP-L18 and cpSRP43-CD2 when the
cpSRP43•LHCP complex was challenged with Alb3CT (Fig.
8C), suggesting that Alb3CT did not induce the release of L18
from cpSRP43. Together, these results support a model in which
Alb3CT induces cpSRP43 into a distinct conformation in which
the substrate TMDs are released, whereas the L18 motif of
LHCP remains bound to the chaperone.
Discussion
Membrane proteins pose special challenges to protein homeo-
stasis during their posttranslational targeting and require highly
effective chaperones. Compared with chaperones that facilitate
Fig. 8. Alb3CT uncouples the interaction of cpSRP43 with the L18 motif and
TMD of LHCP. (A) Binding of HiLyte-Fluor488–labeled L11 peptide to cpSRP43
with (blue) and without (red) Alb3CT present, measured using fluorescence
anisotropy. The data were fit to Eq. 2 and gave Kd values of 22 and 11 nM in
the absence and presence of 20 μMAlb3CT, respectively. (B) Binding of the L18
peptide to cpSRP43 in the absence (red) and presence (blue) of Alb3CT,
measured by using L18 as a competitor of HiLyte-Fluor488–labeled L11 peptide
in binding cpSRP43. The data were fit to Eq. 3 and gave Kappi values of 1.1 and
0.68 μM in the presence and absence of Alb3CT, respectively. (C) (Left) Scheme
of the FRET-based LHCP release assay (Materials and Methods). (Right) FRET
efficiency between Atto488-labeled LHCP (at L18) and TMR labeled cpSRP43
before and after challenge by Alb3CT. Values reported are mean ± SD, with
n = 2. (D) Model for the chaperone cycle of cpSRP43 during LHCP targeting
and insertion, as described in the text. TMD, transmembrane domain; SBD,
substrate binding domain; M2, Alb3CT motif II; M4, Alb3CT motif IV.
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the folding of soluble proteins, membrane protein chaperones
not only handle much more aggregation-prone client proteins,
but must also regulate their substrate binding and release in
response to spatial cues. Here, we define the complete chaperone
cycle for cpSRP43, an ATP-independent chaperone dedicated to
integral membrane proteins. Our results reveal a remarkably
modular nature of this chaperone, wherein substrate binding and
spatial regulations are mediated by distinct domains. Most im-
portantly, the SBD of cpSRP43 intrinsically samples at least
three distinct conformations. This conformational sampling en-
ables this chaperone to be readily switched on by activators in
the stroma and switched off by a negative regulator at the target
membrane, driving highly coordinated substrate capture and
release despite the lack of ATPase cycles.
Substrate Binding Domain Samples Multiple Conformations. Re-
markably, a 25-kDa fragment in cpSRP43 comprised of CD1, the
ankyrin repeats, and the bridging helix was sufficient for stoi-
chiometric binding and chaperoning of LHCP by cpSRP43.
Combined with previous mutational work that tested the effects
of deleting CD1 and individual ankyrin repeats (19), this defines
the CD1Ank-BH fragment as the minimal substrate binding
domain for cpSRP43. How this small chaperone domain protects
client proteins, which match its own size and contain three TMDs,
will be the next challenging question.
Importantly, the SBD of cpSRP43 intrinsically samples mul-
tiple conformations. This property is most directly visualized in
the 1H-15N TROSY spectra of cpSRP43, in which at least two
distinct conformations in slow exchange gave rise to pairs of
component cross-peaks for the same backbone NH. Although
component cross-peaks are unambiguously assigned for 12 resi-
dues reported here, the number of cross-peaks in the TROSY
spectrum is ∼50% greater than the number of residues in
cpSRP43, indicating that many more residues undergo analogous
conformational sampling. A recent single molecule study also
revealed a high degree of conformational fluctuation in cpSRP43
(24). Our ability to isolate a large set of superactive and defective
mutations that lock this chaperone into distinct conformations
provides further evidence for this model. Importantly, the relative
intensity of the component cross-peaks in the TROSY spectra
strongly correlate with chaperone activity in different cpSRP43
variants and in the presence of different regulators (more dis-
cussions below). Based on these observations, we propose that
the SBD samples between an open conformation unable to bind
substrates and a closed conformation conducive to tight sub-
strate binding (Fig. 8D, Upper).
SBD Is Activated by cpSRP54 in the Soluble Phase. Although CD2
does not directly bind substrate proteins, molecular events in this
domain regulate substrate binding in the neighboring SBD. In-
triguingly, CD2 by itself reduces substrate binding in the SBD
and biases cpSRP43 toward the less active open conformation.
Combined with the ability of a large number of point mutations
in CD2 to hyperactivate cpSRP43 and drive the SBD to the
closed conformation, these observations suggest the presence of
strong evolutionary pressure to maintain a substantial population
of apo-cpSRP43 in the inactive conformation, i.e., to keep this
chaperone at the tipping point of conformational transitions.
This conformational property enables cpSRP43 to be readily
turned on by cpSRP54 in the stroma. The C-terminal tail of the
cpSRP54 M-domain intercalates between the bridging helix and
CD2, placing it at an optimal position for regulating interdomain
interactions (23). In support of this model, we found here that
54M or the 54M peptide stimulates the chaperone activity of
SBD. A recent study also found that cpSRP54 enhanced binding
of L18 to cpSRP43 threefold (24). Our observation that the
stimulatory effect of 54M is largely bypassed in superactive
chaperone mutants and becomes more pronounced in defective
chaperone mutants further indicates that 54M and superactive
mutations in CD2 drive the same activating conformational change
in the SBD. This 54M-driven rearrangement allows cpSRP43
to efficiently capture and tightly bind its substrates in the stroma,
effectively protecting LHCPs from aggregation in the aqueous
environment (Fig. 8D, Upper Right).
The structural basis of the communication between CD2,
54M, and SBD remains a challenging question for future studies.
Nevertheless, the available data provide intriguing clues. As
mutations in the linker bridging the SBD and CD2 can lead to
gain or loss of function, communication likely involves reor-
ientation of CD2 relative to the SBD. This model is consistent
with previous small angle X-ray scattering (SAXS) analysis (23)
and with the observation of enhanced FRET efficiency between
dye pairs in Ank3 and CD2 on cpSRP54 binding (24). The BH,
which connects the ankyrin repeat domain to CD2 and whose
deletion drives cpSRP43 into the inactive state, provides a prime
candidate for mediating interdomain communication. Never-
theless, multiple residues in CD1 can sense the binding of L18
and 54M, which binds >50 Å away, indicating that substrate
and 54M induces long-range communications that propagates
through the entire length of the SBD.
Bidentate Interactions of Alb3CT Drive Coordinated Substrate Release.
At the target membrane, cpSRP43 must facilely release its sub-
strate to the Alb3 translocase. The finding that cpSRP43 directly
interacts with the stromal domain of Alb3 (25, 27, 30) provides an
attractive mechanism to couple the release of substrate to its cor-
rect localization and imminent insertion into membrane. Never-
theless, where and how cpSRP43 interacts with Alb3 has been
highly controversial, with the ankyrin repeat domain or the chro-
modomains alternatively proposed as Alb3 binding sites (25–
27, 29). Here, high-resolution NMR combined with bio-
chemical analyses resolved this issue and showed that Alb3CT
uses motifs II and IV to make bidentate interactions with both the
SBD and CD3 of cpSRP43, respectively. As these sites are distinct
from the 54M binding site (located in CD2), this rationalizes the
observation that cpSRP43 can form a ternary complex with both
cpSRP54 and Alb3CT in the NMR studies here and in previous
pull-down experiments (25). The fact that Alb3CT and cpSRP54
biases cpSRP43 to different conformations also explains the anti-
cooperative binding between these two factors (24, 25). Given the
predominantly electrostatic nature of the interaction between
CD3 and Alb3 motif IV, it is likely that the acidic patch on CD3
provides the site for initial recruitment of Alb3CT (29), which
then enables Alb3 motif II to further contact the SBD to induce
substrate release.
Intriguingly, Alb3CT specifically induces the release of sub-
strate TMDs from cpSRP43 without disrupting the interaction of
the L18 motif with the chaperone. This observation has several
important implications. First, Alb3CT does not simply reverse
the effect of 54M and drive cpSRP43 to the completely inactive
open conformation. Instead, Alb3CT induces a third, semiopen
state of cpSRP43 in which its interactions with the L18 and
TMDs on substrate protein are uncoupled (Fig. 8D, Lower).
Second, this suggests a highly coordinated mechanism of sub-
strate release at the membrane, in which the TMDs are first
released and could initiate their membrane insertion via Alb3,
whereas the L18 loop of LHCP remains bound to cpSRP43.
Formation of such a LHCP•cpSRP•Alb3 release complex at the
membrane is consistent with the previous observation that
cpSRP43 was trapped into high molecular weight species with
LHCP on addition of Alb3CT (27). In contrast to the current
mechanisms in which LHCP is completely released from cpSRP43,
such a stepwise mechanism would minimize irreversible aggregation
of LHCP and abortive targeting reactions, providing a more pro-
ductive route for unloading the membrane protein substrate onto
the translocase.
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Summary. Our work here defines a rigorous framework for the
chaperone cycle of cpSRP43 (Fig. 8D). The SBD of cpSRP43
samples at least three conformational states: an open state
(Upper Left), a closed state (Upper Right), and semiopen state
that binds tightly to L18 but not the TMDs of LHCP (Lower).
CD2 biases the SBD to the open state, whereas interaction with
cpSRP54 drives cpSRP43 to the closed state that binds LHCP
tightly. When the transit complex is targeted to the thylakoid
membrane via the interaction of cpSRP54 with cpFtsY, Alb3CT
uses motifs II and IV (M2 and M4) to make bidentate interac-
tions with SBD and CD3 of cpSRP43, respectively. These inter-
actions induce cpSRP43 to a semiopen conformation, triggering
the release of the substrate TMDs from cpSRP43 and initiating
their membrane insertion, whereas the L18 motif remains bound
to cpSRP43. Ultimate release of L18 from cpSRP43 might be
driven by folding of LHCP in the membrane and binding of
photosynthetic pigments.
Although cpSRP43 is dedicated to the LHCP family of pro-
teins, it embodies multiple new concepts that have emerged from
the recent discovery of a wide array of chaperones: (i) the use of
protein interaction energy instead of ATPase cycles to regulate
substrate binding/release, which is found in cyclophilins (34),
small heat-shock proteins (35–38), and all of the chaperones in
the bacterial periplasmic or eukaryotic extracellular space; and
(ii) the use of conformational flexibility for activation, which was
also found in HdeA, Hsp33, and Hsp26 (39, 40), and may be a
general feature of ATP-independent chaperones. The mecha-
nism we describe here for cpSRP43 could facilitate under-
standing of these conceptually analogous chaperone systems, as
well as methods for their investigation.
Materials and Methods
Protein Expression and Purification. cpSRP43 and Alb3CT mutants were con-
structed using the QuikChange procedure (Stratagene). CD1Ank constructs
were deleted residues from 253 to 266 compared with CD1Ank-BH. In the
linker mutants Intein (GSCFNGT) and GSGSG, the indicated sequences were
inserted between V266 and F267. In mutant 2P, two prolines replaced the
original linker residues (Q265 and V266). WT and mutant cpSRP43 and LHCP
were overexpressed and purified as previous described (41). Alb3CT was
overexpressed in BL21(DE3) cells and purified as previously described (25).
54M peptide (QKAPPGTARRKRKAC) was from Eton Bioscience (99% purity).
Peptides L11 (GSFDPLGLADD), L18 (VDPLYPGGSFDPLGLADD), and L11 la-
beled with HiLyte-Fluor488 were purchased from AnaSpec (>95% purity).
Single cysteine mutants of cpSRP43 and LHCP were labeled with fluorescent
dyes via maleimide chemistry with 80–90% efficiency. Labeled proteins were
purified through Sephadex G25 to remove free dye.
Chaperone Activity of cpSRP43. Two types of experiments were used. First, we
measured the ability of cpSRP43 to prevent LHCP aggregation, as described
previously (19, 22). Briefly, urea denatured LHCP was diluted into buffer
containing varying concentrations of cpSRP43, and light scattering at 360 nm
was measured over time until equilibrium was reached. The percentage of
soluble LHCP (% soluble) at equilibrium was plotted as a function of cpSRP43
concentration. The data were fit to
%  soluble=ΔA
½LHCP+ ½pro+Kd −
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½LHCP+ ½pro+KdÞ2 − 4½LHCP½pro
q
2½LHCP ,
[1]
in which [pro] is cpSRP43 concentration, ΔA is the soluble% at saturating
cpSRP43 concentrations, and Kd is the apparent dissociation constant of
LHCP interaction with cpSRP43.
Second, we measured the ability of cpSRP43 to reverse preformed LHCP
aggregates. LHCP (1 μM) was aggregated in buffer for 1 min, followed by
addition of 4–5 μM WT or mutant cpSRP43, and the clearance of large LHCP
aggregates was followed in real time by light scattering at 360 nm.
Measurement of L18 Binding. The interaction of L18 with cpSRP43 was
assessed by two methods. First, binding of cpSRP43 to HiLyte-Fluor488–la-
beled L11 peptide, which contains the minimal interaction sequence in L18,
was detected by changes in fluorescence anisotropy of the dye. Anisotropy
measurements were conducted in buffer D (50 mM KHepes, pH 7.5, 200 mM
NaCl) on Fluorolog 3–22 (Yobin Yvon), using 100 nM HiLyte-Fluor488–
labeled L11 and varying concentrations of cpSRP43. The samples were ex-
cited at 500 nm, and the fluorescence anisotropy was recorded at 527 nm.
The data were fitted to
Aobsd =A0 +ΔA
½L11+ ½pro+Kd −
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½L11+ ½pro+KdÞ2 − 4½L11½pro
q
2½L11 , [2]
in which Aobsd is the observed anisotropy value, A0 is the anisotropy value
without cpSRP43, ΔA is the change in anisotropy at saturating cpSRP43
concentrations, and Kd is the equilibrium dissociation constant for cpSRP43
interaction with L11-HiLyte-Fluor488.
To independently measure the L18-cpSRP43 interaction without pertur-
bations from the dye, unlabeled L18 peptide was used as a competitor for the
binding of L11-HiLyte-Fluor488 to cpSRP43; 100 nM L11-HiLyte-Fluor488 was
preincubated with 120 nM cpSRP43 for 5 min, and the complex was chal-
lenged with an increasing concentration of L18 peptide. Anisotropy values
were recorded at equilibrium and plotted as a function of [L18]. The data
were fit to
Aobsd =A0 −ΔA
½L18
½L18+Kappi
, [3]
in which Aobsd is the observed anisotropy value, A0 is the anisotropy value
without L18 present, ΔA is the change in anisotropy at saturating L18 con-
centrations, and Kappi is the apparent inhibition constant.
Alb3CT Binding to cpSRP43. Binding was detected by two methods. First,
Alb3CT(S371C) was labeled with fluorescein-5′-maleimide (Invitrogen), and
labeled protein was purified through Sephadex G25 (Sigma) to remove free
dye. Binding of fluorescein-labeled Alb3CT(S371C) to cpSRP43 was detected
by changes in fluorescence anisotropy, measured as described for L11
binding except that 200 nM Alb3CT(S371C)-fluorescein was used instead of
L11. Samples were excited at 495 nm, and the fluorescence anisotropy was
recorded at 512 nm. The data were fit to Eq. 2, with the exception that
[Alb3CT] replaces [L11].
Second, unlabeled Alb3CT was used as competitors in the interaction of
cpSRP43 with Alb3CT(S371C)-fluorescein; 200 nM Alb3CT-S371C-fluorescein
was preincubated with 10 μM cpSRP43 for 5 min, and the complex was
chased with increasing concentrations of WT or mutant Alb3CT. Fluores-
cence anisotropy values were recorded at equilibrium and plotted as a
function of competitor concentration. The data were fit to Eq. 3, with the
exception that [Alb3CT] replaces [L18].
Alb3-Induced Substrate Release. LHCP release was evaluated by two methods.
First, a soluble LHCP•cpSRP43 complex was performed in buffer D using 1 μM
LHCP and 5 μM cpSRP43. After 1-min incubation, the complex was chased
with Alb3CT, and the reaction was monitored in real time by light scattering
at 360 nm. Second, a single cysteine LHCP mutant (C80A,G158C) was labeled
with Atto488 maleimide in the middle of L18. A single cysteine mutant of
cpSRP43 (C175A-C297) was labeled with TMR-5-maleimide (Invitrogen). La-
beled LHCP (50 nM) and cpSRP43 (2 μM) were preincubated for 5 min in
buffer D with 0.1 mg/mL BSA, followed by addition of 5 μM Alb3CT. Fluo-
rescence was monitored on a Fluorolog 3–22 spectrofluorometer (Jobin
Yvon) using an excitation wavelength of 505 nm and emission wavelength
of 525 nm. A control release reaction was performed using unlabeled
cpSRP43 to obtain the intensity for the donor sample (ID). FRET efficiency
was calculated as
FRET  efficiency=  
ID − IDA
ID
, [4]
in which IDA is the fluorescence intensity of donor in the presence of
acceptor-labeled cpSRP43.
NMR Spectroscopy. Multidimensional NMR spectra were recorded on Bruker
Avance spectrometers operating at 800 and 900 MHz. All NMR spectra
were acquired at 17 °C using 2H, 15N-labeled or 2H, 15N, 13C-labeled protein
(∼0.2 mM) in NMR buffer containing 10% (vol/vol) D2O at pH 6.5. Titration
experiments were performed by serial addition of unlabeled ligands into the
NMR sample containing 2H, 15N-labeled cpSRP43. NMR data were processed
with NMRPipe (42) and analyzed with NMRView Java (43). Details on
NMR sample preparation and assignments are described in SI Materials
and Methods.
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